Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 249, Issue 5, 2011, Pages 639-644

  Heimes, Britta ^a   Lommatzsch, Albrecht ^a   Zeimer, Meike ^a   Gutfleisch, Matthias ^a   Spital, Georg ^a   Dietzel, Martha ^a   Pauleikhoff, Daniel ^a  

^a ST FRANZISKUS HOSPITAL   (Germany)

Author keywords

Anti VEGF therapy; Autofluorescence; CNV; Exudative AMD; Microperimetry; OCT; Predictive factor; Prognostic factor

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL EVALUATION; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; EXUDATIVE MACULAR DEGENERATION; FEMALE; FOLLOW UP; GERMANY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA EDEMA; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; GERMANY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RETINA; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISION DISORDERS; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 79955620226     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-010-1524-5     Document Type: Article

References (10)

1. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New Engl J Med 355:1432-1444 (Pubitemid 44511558)
2. EMEA (2007) Lucentis: Scientific Discussion http://www.ema. europa.eu/humandocs/PDFs/EPAR/lucentis/H-715-en6.pdf. Accessed 16 May 2010
3. EMEA (2007) Lucentis: Summary of product characteristics http://www.ema.europa.eu/humandocs/PDFs/EPAR/lucentis/ emea-combined-h715en.pdf. Accessed 16 May 2010
4. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566-583
5. Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Schmidt-Erfurth U, Wolf S, Markabi S, Schmidli H, Weichselberger A (2010) The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 51:405-412
6. Kaiser PK, Blodi BA, Shapiro H, Acharya NR (2007) Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114:1868-1875
7. Meyer CH, Eter N, Holz FG, SUSTAIN Study Group (2008) Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN Trial. Invest Ophthalmol Vis Sci 49:273
8. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239-248
9. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. New Engl J Med 355:1419-1431 (Pubitemid 44511557)
10. Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE (2009) Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 147:831-837